Experimentally, we constructed a novel recombinant oncolytic vaccinia virus encoding an EpCAM BiTE (VV-EpCAM BiTE), which was able to efficiently replicate and lyse tumor cells in vitro, and efficiently activated intratumoral immune responses without exogenous stimulation resulting in improved antitumor outcomes in EpCAM positive malignancies. The gene discussed is EPCAM; the disease is neoplasm.